OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
1.950
-0.050 (-2.50%)
May 9, 2025, 11:17 AM - Market open

OnKure Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
13.0910.374.823.9
Research & Development
47.6243.1732.1225.86
Operating Expenses
60.7153.5436.9329.77
Operating Income
-60.71-53.54-36.93-29.77
Interest Expense
-0.15-0.15--
Interest & Investment Income
2.792.011.620.25
Other Non Operating Income (Expenses)
-0.04-0.04--
EBT Excluding Unusual Items
-58.1-51.71-35.31-29.51
Merger & Restructuring Charges
-0.23-0.23--
Other Unusual Items
-0.74-0.74--
Pretax Income
-59.06-52.67-35.31-29.51
Net Income
-59.06-52.67-35.31-29.51
Net Income to Common
-59.06-52.67-35.31-29.51
Shares Outstanding (Basic)
730-
Shares Outstanding (Diluted)
730-
Shares Change (YoY)
-49.42%1114.54%--
EPS (Basic)
-8.78-15.28-124.41-
EPS (Diluted)
-8.79-15.28-124.41-
Free Cash Flow
--51.17-34.79-28.09
Free Cash Flow Per Share
--14.84-122.59-
EBITDA
-60.25-53.08-36.52-29.54
D&A For EBITDA
0.460.460.420.23
EBIT
-60.71-53.54-36.93-29.77
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q